{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:05:17Z","timestamp":1784203517743,"version":"3.55.0"},"reference-count":50,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CPT Pharmacom &amp; Syst Pharma"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>CAR\u2010T cell therapy is a cellular cancer immunotherapy that has impressively improved outcomes in hematological malignancies compared to conventional treatments. Yet, many patients do not respond permanently. Nonlinear mixed\u2010effects modeling can support a better understanding of the unique and not fully understood dose\u2010exposure and exposure\u2010response relationships for CAR\u2010T cell therapy by integrating available knowledge into a quantitative, physiology\u2010motivated framework. However, to unfold its full potential, it requires informative and efficient study designs for clinical data collection. We aimed to develop an optimal experimental design framework informing a robust and feasible clinical CAR\u2010T cell study design based on a published mechanistic model of CAR\u2010T cell kinetics and tumor dynamics. By considering variability between study populations and parameter uncertainty, we (1) identified the minimal population size required to inform model parameters, (2) assessed different sampling strategies, and (3) informed flexible sampling windows instead of fixed sampling timepoints. The optimized study design consisted of 60 patients, three fixed assessments of tumor burden (days 0, 30 and 90), and three feasible CAR\u2010T cell sampling windows (days 2\u20134, 12\u201318 and 32\u201347 after infusion). In stochastic simulation and estimation, the optimized design with sampling windows showed better performance in informing model parameters, including those characterizing heterogeneous outcomes, than designs with fixed sampling timepoints, confirming its efficiency and robustness. This framework shall facilitate future feasible and resource\u2010efficient CAR\u2010T cell clinical data collection, thus showcasing the potential of optimal experimental design to advance the development and optimization of complex cancer immunotherapies in clinical trials and clinical practice.<\/jats:p>","DOI":"10.1002\/psp4.70274","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:27:07Z","timestamp":1783430827000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing Clinical Study Designs for\n                    <scp>CAR<\/scp>\n                    \u2010T Cell Therapy: Development of an Efficient Sampling Strategy Through Optimal Experimental Design"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8504-9788","authenticated-orcid":false,"given":"Fenja","family":"Klima","sequence":"first","affiliation":[{"name":"Freie Universit\u00e4t Berlin Institute of Pharmacy, Department of Clinical Pharmacy and Biochemistry  Berlin Germany"},{"name":"Graduate Research Training Program PharMetrX  Berlin, Potsdam Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5936-1877","authenticated-orcid":false,"given":"Anna M.","family":"Mc Laughlin","sequence":"additional","affiliation":[{"name":"Freie Universit\u00e4t Berlin Institute of Pharmacy, Department of Clinical Pharmacy and Biochemistry  Berlin Germany"},{"name":"Graduate Research Training Program PharMetrX  Berlin, Potsdam Germany"},{"name":"Pharmetheus AB  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-607X","authenticated-orcid":false,"given":"Robin","family":"Michelet","sequence":"additional","affiliation":[{"name":"Freie Universit\u00e4t Berlin Institute of Pharmacy, Department of Clinical Pharmacy and Biochemistry  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5249-3914","authenticated-orcid":false,"given":"Wilhelm","family":"Huisinga","sequence":"additional","affiliation":[{"name":"Graduate Research Training Program PharMetrX  Berlin, Potsdam Germany"},{"name":"Institute of Mathematics University of Potsdam  Potsdam Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Haussmann","sequence":"additional","affiliation":[{"name":"Berlin Center for Advanced Therapies Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt\u2010Universit\u00e4t zu Berlin, and Berlin Institute of Health  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8406-5412","authenticated-orcid":false,"given":"Annette","family":"K\u00fcnkele","sequence":"additional","affiliation":[{"name":"Berlin Center for Advanced Therapies Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt\u2010Universit\u00e4t zu Berlin, and Berlin Institute of Health  Berlin Germany"},{"name":"Department of Pediatric Oncology and Hematology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt\u2010Universit\u00e4t zu Berlin, and Berlin Institute of Health  Berlin Germany"},{"name":"German Cancer Consortium (DKTK), partner Site Berlin and German Cancer Research Center (DKFZ)  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2676-5912","authenticated-orcid":false,"given":"Andrew C.","family":"Hooker","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9344-8514","authenticated-orcid":false,"given":"Charlotte","family":"Kloft","sequence":"additional","affiliation":[{"name":"Freie Universit\u00e4t Berlin Institute of Pharmacy, Department of Clinical Pharmacy and Biochemistry  Berlin Germany"},{"name":"Graduate Research Training Program PharMetrX  Berlin, Potsdam Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1"},{"issue":"19","key":"e_1_2_10_3_1","first-page":"2307","article-title":"Five\u2010Year Follow\u2010Up of ZUMA\u20101 Supports the Curative Potential of Axicabtagene Ciloleucel in Refractory Large B\u2010Cell Lymphoma","volume":"141","author":"Neelapu S. S.","year":"2023","journal-title":"Blood"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00760"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301665"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00832-4"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01139-z"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011992"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13011"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003092"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002394"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001900"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112782"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02539-9"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00689-z"},{"issue":"15","key":"e_1_2_10_16_1","first-page":"3378","article-title":"Phenotypic Composition of Commercial Anti\u2010CD19 CAR T Cells Affects In\u00a0Vivo Expansion and Disease Response in Patients With Large B\u2010Cell Lymphoma","volume":"28","author":"Monfrini C.","year":"2022","journal-title":"Nature Reviews Clinical Oncology"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02129-y"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43588-022-00377-z"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105597"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-024-00355-3"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.14"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114421"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-2607(03)00073-7"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12713"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-005-2102-z"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.1509"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-005-0026-2"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021620"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-24-0118"},{"key":"e_1_2_10_31_1","unstructured":"C.Vong S.Ueckert J.Nyberg andA. C.Hooker \u201cHandling Below Limit of Quantification Data in Optimal Trial Design \u201d(2012) http:\/\/www.page\u2010meeting.org\/?abstract=2578."},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9542-0"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118445112.stat04090.pub2"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2012.05.005"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-10-181"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03247.x"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.29095"},{"issue":"2","key":"e_1_2_10_38_1","first-page":"324","article-title":"FDA Experience on CAR T Cell Pharmacokinetics\/Pharmacodynamics and Model\u2010Based Assessments","volume":"118","author":"Tegenge M. A.","year":"2025","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.19462"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2509"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01039-5"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12598"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010543"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010364"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005678"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-025-01017-w"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2040"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s42519-019-0073-4"}],"container-title":["CPT: Pharmacometrics &amp; Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.70274","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/psp4.70274","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.70274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:25:01Z","timestamp":1784201101000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.70274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/psp4.70274"],"URL":"https:\/\/doi.org\/10.1002\/psp4.70274","archive":["Portico"],"relation":{},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"value":"2163-8306","type":"print"},{"value":"2163-8306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-02-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70274"}}